Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Halts Phase III Study Of Sutent In Advanced Breast Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Failed single-agent trial is small setback for Sutent, analyst says. Pfizer has three combination trials also ongoing in breast cancer settings.

You may also be interested in...



R&D In Brief

Pfizer halts figitumumab lung cancer trial: Pfizer has stopped a late-stage trial of its insulin-like growth factor 1 inhibitor figitumumab (CP-751,871) in metastatic non-small cell lung cancer, losing the lead in the new oncology space (1Pharmaceutical Approvals Monthly May 2008). Pfizer is continuing with an ongoing trial combining figitumumab with Roche/Genentech's Tarceva in NSCLC; a third planned Phase III trial has not yet started. The Phase III lung cancer trial was halted after the independent data safety monitoring board detected an imbalance in serious adverse events, including fatalities, in the '871, carboplatin and Taxol arm. Pfizer, which has made a major push into oncology, has faced other recent setbacks in cancer, with failed trials of Sutent (sunitinib) in breast cancer and the investigational axitinib in pancreatic cancer (2"The Pink Sheet" DAILY, April 2, 2009)

R&D In Brief

Pfizer halts figitumumab lung cancer trial: Pfizer has stopped a late-stage trial of its insulin-like growth factor 1 inhibitor figitumumab (CP-751,871) in metastatic non-small cell lung cancer, losing the lead in the new oncology space (1Pharmaceutical Approvals Monthly May 2008). Pfizer is continuing with an ongoing trial combining figitumumab with Roche/Genentech's Tarceva in NSCLC; a third planned Phase III trial has not yet started. The Phase III lung cancer trial was halted after the independent data safety monitoring board detected an imbalance in serious adverse events, including fatalities, in the '871, carboplatin and Taxol arm. Pfizer, which has made a major push into oncology, has faced other recent setbacks in cancer, with failed trials of Sutent (sunitinib) in breast cancer and the investigational axitinib in pancreatic cancer (2"The Pink Sheet" DAILY, April 2, 2009)

Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early

Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.

Related Content

Topics

UsernamePublicRestriction

Register

PS069301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel